The PACS Group, Inc. (NYSE: PACS) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, along with AI-powered summaries to help interpret them. As a healthcare holding company in the post-acute care and medical care facilities space, PACS uses SEC reports to describe its facility portfolio, credit arrangements, governance, and risk profile.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q for detailed discussions of PACS Group’s operations, financial condition, and risk factors. These filings also provide context on the company’s role as a holding company, the structure of its independent operating subsidiaries, and the separation between licensed healthcare providers and non-provider entities. AI-generated highlights can point out key sections on post-acute care operations, use of credit facilities, and lease obligations.
Current reports on Form 8-K are particularly important for PACS, given its history of restatements, credit agreement amendments, and NYSE listing updates. Recent 8-K filings have addressed topics such as forbearance and amendments under the company’s amended and restated credit agreement, events of default and related waivers, NYSE listing extensions tied to delayed SEC filings, and the completion of an independent Audit Committee investigation and related restatements. AI summaries can help users quickly understand the implications of these events.
Users can also access proxy materials such as the Definitive Proxy Statement on Schedule 14A, which outlines matters presented to stockholders at the annual meeting, including director elections, auditor ratification, and advisory votes on executive compensation. In addition, the filings page provides real-time updates from EDGAR and convenient access to other forms, such as notifications of late filings on Form 12b-25. Together, these documents offer a comprehensive view of PACS Group’s regulatory history, governance decisions, and financial reporting, with AI tools available to simplify and explain complex disclosures.
PACS Group, Inc. (PACS) Co-Founder, CEO & Chairman and ten percent owner Murray Jason Hulse reported selling a total of 19,617 shares of common stock in three open-market transactions on September 10, 11 and 14, 2026, at weighted average prices around $45 per share.
Each transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 18, 2026, with prices disclosed as weighted averages over ranges between $45.00 and approximately $45.76 per share.
PACS Group, Inc. (PACS) received a notice of proposed sale under Rule 144 for up to 253,333 shares of its common stock through UBS Financial Services Inc. The filing lists an aggregate market value of $11,209,985.25 for these shares and notes 158,335,612 shares outstanding of the same class. The securities to be sold are described as Founders Shares acquired from the issuer on April 11, 2024. The notice also reports multiple sales of common stock during the past three months by a stockholder named Jason Murray, including 84,602 shares sold on August 17, 2026 for $3,736,297.87 and additional smaller blocks sold on subsequent trading days.
PACS Group, Inc. (PACS) disclosed that reporting person Murray Jason Hulse, its Co-Founder, CEO & Chairman and a ten percent owner, sold a total of 51,887 shares of common stock in several open-market or private transactions on September 4, 8 and 9, 2026 under a Rule 10b5-1 trading plan adopted on May 18, 2026. The reported per-share prices are weighted averages, with the underlying trades executed within disclosed price ranges around the low- to mid-$40s per share.
PACS Group, Inc. (PACS) reported that Co-Founder, CEO & Chairman and ten percent owner Murray Jason Hulse sold an aggregate 68,113 shares of common stock in six open-market transactions from September 1–3, 2026. Reported weighted-average prices for the sales ranged from about $41.92 to $43.78 per share, as detailed in transaction-specific ranges.
The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 18, 2026, and all sales were reported as directly owned common stock. The filing does not state the number of shares Mr. Hulse continues to hold after these transactions.
PACS Group, Inc. (PACS) received a notice under Rule 144 that Murray Jason Hulse, through UBS Financial Services Inc. as attorney-in-fact, may sell 120,000 shares of PACS common stock identified as Founders Shares. The notice lists an aggregate market value of approximately $5,070,000 for these shares and states that 158,335,612 PACS common shares were outstanding as of September 1, 2026.
The filing also reports recent open-market sales by Jason Murray over the past three months, reflecting multiple transactions in PACS common stock with disclosed share counts and dollar values.
PACS Group, Inc. (PACS) reported that director and ten percent owner Mark Hancock made a bona fide gift of 88,000 shares of Common Stock on 2026-08-18. The shares were given to a charitable donor-advised fund. Following this gift, Hancock directly holds 53,818,884 Common Stock shares.
PACS Group, Inc. (PACS) director Patrick Hugh Conway reported a sale of company common stock. On 2026-08-14, he sold 3,497 shares of Common Stock in a transaction described as a sale in an open market or private transaction at $44.41 per share. Following this transaction, he directly holds 8,947 shares of PACS Group, Inc. common stock.
PACS Group, Inc. (PACS) director and Co-Founder, CEO & Chairman Murray Jason Hulse reported open-market sales of an aggregate 150,550 shares of common stock on August 20–21, 2026, in multiple transactions at weighted average prices in the low-to-mid $40s per share, effected under a Rule 10b5-1 trading plan adopted on May 18, 2026.
PACS Group, Inc. (PACS) reported insider sales by Co-Founder, CEO & Chairman Murray Jason Hulse. Over August 17–19, 2026, he sold a total of 236,116 shares of common stock in open-market transactions under a Rule 10b5-1 trading plan adopted on May 18, 2026. Reported weighted-average prices ranged from about $42.81 to $44.86 per share, with detailed price breakdowns available on request to the company or the SEC staff.